Form 4: Karyopharm Therapeutics Director Granted Stock Options Following Reverse Stock Split

Karyopharm Therapeutics Inc. Director Mansoor Raza Mirza was granted 4,600 nonstatutory stock options with an exercise price of $4.48, vesting fully on May 28, 2026, as disclosed in a recent SEC Form 4 filing.

Summary

• Mansoor Raza Mirza, a Director of Karyopharm Therapeutics Inc. (KPTI), acquired 4,600 nonstatutory stock options on May 28, 2025.
• The options have an exercise price of $4.48 per share.
• These options will vest as to 100% of the underlying shares on May 28, 2026.
• The expiration date for these options is May 27, 2035.
• All amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation disclosure rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

The stock option grant, with its vesting schedule extending to May 2026, indicates a continued commitment and alignment of the director's interests with the company's future performance and shareholder value creation.

Management Comments

• The filing was signed by Nancy Smith, Attorney-in-Fact for Mansoor Raza Mirza.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to attract and retain talent, and to align their financial incentives with the long-term success of the company.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across the biotech and pharmaceutical sectors, similar to companies like BioNTech SE or Moderna, Inc., which also utilize equity-based incentives to align director interests with company performance.
• The specific number of options (4,600) and exercise price ($4.48) would typically be evaluated against Karyopharm's peer group compensation benchmarks and the company's overall market capitalization and stage of development, though specific comparable data is not provided in this filing.

Related Party Transactions

• Mansoor Raza Mirza, a Director of Karyopharm Therapeutics Inc., was granted 4,600 nonstatutory stock options as part of his compensation, representing a related party transaction.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While not directly impacting employees, such compensation structures for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The granted stock options will vest on May 28, 2026, at which point the director will have the right to exercise them.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Reverse Stock Split